



Celislon Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapy Summit

November 6, 2021

Chief Science Officer Richard A. Jones, PhD

LOS ANGELES, N.Y., Nov. 6, 2021 (GLOBE NEWSWIRE) -- Celislon Corporation (NASDAQ: CLON) is proud to announce its participation in the Cytokine-Based Cancer Immunotherapy Summit being held in Boston on November 10 and 11, 2021. Dr. Jones will also be participating in two panel discussions.

In his presentation, Dr. Jones will discuss the use of IL-12 in cancer immunotherapy, including its use in a novel gene-based approach for the treatment of melanoma. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy.

Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy.

About GEN-1 Immunotherapy

GEN-1 is a novel immunotherapy that combines the use of IL-12 with a novel gene-based approach for the treatment of melanoma. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy. Dr. Jones will also be participating in a panel discussion on the use of IL-12 in cancer immunotherapy.

Forward Looking Statements

This press release contains certain forward-looking statements. These statements are based on the current information available to the Company as of the date of this press release. The Company disclaims any obligation to update these forward-looking statements.

Contact Us

Richard A. Jones, PhD

Chief Science Officer

10000 Wilshire Blvd

Suite 1000

Beverly Hills, CA 90210

Phone: 310.434.1000

www.celislon.com

Source: Celislon Corporation



Source: Celislon Corporation